ArticleFrontiers in pharmacology2024

A case report: deep and durable response to low-dose lenvatinib and tislelizumab in an elderly patient with advanced intrahepatic cholangiocarcinoma.

Pei Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.